Stockscreener 앱 받기
20.65
1.29%
0.2753
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals' Revuforj® Recognized as Best New Drug at 2025 Scrip Awards - Quiver Quantitative
(SNDX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentCandlestick Pattern Analysis & Rapid Portfolio Expansion - earlytimes.in
Jump Financial LLC Makes New $3.57 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week HighHere's Why - MarketBeat
Syndax Pharmaceuticals (SNDX) Valuation After Strong New Revuforj Data at Major Hematology Meeting - Sahm
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Stempoint Capital LP - MarketBeat
Hsbc Holdings PLC Boosts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research - MarketBeat
SNDX: BTIG Reiterates "Buy" Rating with Price Target of $56 | SN - GuruFocus
TD Cowen reiterates Buy rating on Syndax Pharmaceuticals stock By Investing.com - Investing.com Canada
Should New Revuforj Leukemia Data From ASH 2025 Require Action From Syndax Pharmaceuticals (SNDX) Investors? - Sahm
Syndax Pharmaceuticals (SNDX): Valuation Check After Positive Revuforj Data at the 67th ASH Meeting - Yahoo Finance
Is Syndax Pharmaceuticals Fairly Priced After Recent Oncology Pipeline Momentum? - Yahoo Finance
Transcript : Syndax Pharmaceuticals, Inc. Presents at The 67th American Society of Hematology Annual Meeting, Dec-08-2025 07 - marketscreener.com
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum - The Manila Times
Syndax Pharmaceuticals Highlights Promising Efficacy and Safety Data for Revuforj® at the 67th ASH Annual Meeting - Quiver Quantitative
Syndax (Nasdaq: SNDX) posts 92% CRc in Phase 1 revumenib AML combo data at ASH 2025 - Stock Titan
Schroder Investment Management Group Buys 64,598 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Tema Etfs LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Syndax Pharmaceuticals stock hits 52-week high at 20.25 USD By Investing.com - Investing.com Australia
Saturn V Capital Management LP Sells 540,729 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stonepine Capital Management LLC Buys New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Capital Fund Management S.A. Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Why Syndax Pharmaceuticals Inc. (1T3) stock could rally strongly2025 Macro Impact & Weekly Watchlist for Consistent Profits - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsQuarterly Portfolio Report & Verified Momentum Watchlists - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Is Syndax Pharmaceuticals Inc. (1T3) stock a buy during volatile marketsCPI Data & Safe Capital Growth Tips - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock positioned for digital growth eraWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Syndax Pharmaceuticals (SNDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Syndax Pharmaceuticals Inc a good long term investmentEarnings Growth Projections & Maximize Returns With Insights - earlytimes.in
What insider purchases suggest about Syndax Pharmaceuticals Inc. (1T3) stockMarket Movement Recap & High Accuracy Swing Entry Alerts - Newser
Can Syndax Pharmaceuticals Inc. (1T3) stock reach $200 price targetCEO Change & High Return Trade Opportunity Guides - Newser
CFO Goldan Gifts 1,224 Of Syndax Pharmaceuticals Inc [SNDX] - TradingView
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference - The Manila Times
Geode Capital Management LLC Has $19.20 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Analyst Calls & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Syndax Pharmaceuticals, Inc. $SNDX is Aisling Capital Management LP's 3rd Largest Position - MarketBeat
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha
Syndax Pharmaceuticals, Inc. $SNDX Stock Position Boosted by Franklin Resources Inc. - MarketBeat
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating - MSN
10 Most Promising Stocks with Huge Upside Potential - Insider Monkey
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Rhenman & Partners Asset Management AB - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 10.9% Higher After Analyst Upgrade - MarketBeat
Syndax Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating - MSN
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $35.00 at Barclays - MarketBeat
Barclays Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation - Nasdaq
SNDX Analyst Update: Barclays Raises Price Target to $35 | SNDX Stock News - GuruFocus
0.56%
1.23%
자본화:
|
볼륨(24시간):